EFFICACY AND SAFETY OF CLADRIBINE: SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION IN HAIRY CELL LEUKEMIA PATIENTS
Cladribine induces durable complete remission (CR) in approximately 85% of hairy cell leukemia (HCL) patients. In Egypt, cladribine is mainly used as IV continuous infusion at a dose of 0.1 mg/kg/day for 7 days and as SC bolus injection at a dose of 0.14 mg/kg/day for 5 days. We aimed to compare the...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mattioli1885
2015-10-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/2174 |